Home Southwest Austin, TX Aspira Women's Health COMPANY
3 open jobs · last seen Oct 23, 2026 · 5 sources
Keywords: diagnostics Adnexal Mass Endometriosis Germline BRCA1 Gene Mutation Germline BRCA2 Gene Mutation Hereditary Breast and Ovarian Cancer OVAnex Show all 7 keywords
Location: Austin, TX · source · Oct 14, 2026
Profile checked Oct 10, 2026
Hiring Title Location (from posting) Employer posted First seen Market Development Mgr Remote, FL, US Apr 15, 2026 Oct 11, 2026 Market Development Mgr Houston, TX, US Apr 6, 2026 Oct 11, 2026 Insurance Reimbursement Specialist Shelton, CT, US Mar 2, 2026 Oct 11, 2026
See all 3 jobs
At a glance HQ Austin, TX source Region Southwest Latest trial —: Deep Neural Network Stratification for Use Detecting Endometriosis in Women Affected by Chronic Pelvic Pain… (Jul 12, 2022) source Funding and NIH signals SEC Form D raise Raised $1.49M (Form D filed Jun 22, 2026); 3 roles open. SEC Form D 0001104659-26-076151 (Jun 22, 2026)Evidence (1 event) Jun 22, 2026 · SEC Form D 0001104659-26-076151 Name of Issuer: Aspira Women's Health Inc.; CIK: 926617; Address: Austin, TX; Submission type: D; Filing date: 2026-06-22; Industry Group: Biotechnology; Date of First Sale: 2026-06-05; Types of Securities Offered: Equity, Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 1485000; Total Amount Sold: 1485000; Federal exemptions: 06b Job counts as of Oct 18, 2026. All funding and NIH signals
Timeline May 26, 2026 Partnership Partnership / licensing announced May 26, 2026. Source: SEC filing. source ↗ Oct 23, 2024 Grant Government grant: $10M (total, as published), announced Oct 23, 2024. Source: SEC filing. source ↗ Jul 12, 2022 Trial start —: Deep Neural Network Stratification for Use Detecting Endometriosis in Women Affected by Chronic Pelvic Pain (EndoCheck) source ↗ Jun 25, 2020 Trial start —: A Multivariate Index Assay for Ovarian Cancer Risk Assessment in Women With Adnexal Mass and High-Risk Germline Variants source ↗ May 4, 2020 Trial start —: Multifactorial Risk Assessment for Breast & Ovarian Cancer Risk Detection source ↗ Funding Last 2 years.
May 26, 2026 Partnership / licensing announced May 26, 2026. Source: SEC filing. source ↗ Oct 23, 2024 Government grant: $10M (total, as published), announced Oct 23, 2024. Source: SEC filing. source ↗ Clinical trials (lead sponsor) 3 Record Title Phase Status Start Primary completion NCT05245695 Deep Neural Network Stratification for Use Detecting Endometriosis in Women Affected by Chronic Pelvic Pain (EndoCheck) Not listed Recruiting Jul 12, 2022 Jun 30, 2026 (estimated) NCT04487405 A Multivariate Index Assay for Ovarian Cancer Risk Assessment in Women With Adnexal Mass and High-Risk Germline Variants Not listed Terminated Jun 25, 2020 Dec 15, 2023 (actual) NCT04668521 Multifactorial Risk Assessment for Breast & Ovarian Cancer Risk Detection Not listed Terminated May 4, 2020 Dec 15, 2023 (actual)
Raises and investors new Form D raises come from the company’s own SEC filing (last 2 years).
2026-06-22 Raise Private raise (SEC Form D): $1.5M sold; issuer “Aspira Women's Health Inc.”. Verified from the SEC filing. SEC filing ↗ 2025-09-18 Raise Private raise (SEC Form D): $3.0M sold; issuer “Aspira Women's Health Inc.”. Verified from the SEC filing. SEC filing ↗ 2025-03-20 Raise Private raise (SEC Form D): $1.4M sold; issuer “Aspira Women's Health Inc.”. Verified from the SEC filing. SEC filing ↗ Open jobs 3 Title Location (from posting, not HQ) Employer posted First seen Level Market Development Mgr Remote, FL, US Apr 15, 2026 Oct 11, 2026 Mid Description Market Development Mgr Houston, TX, US Apr 6, 2026 Oct 11, 2026 Mid Description Insurance Reimbursement Specialist Shelton, CT, US Mar 2, 2026 Oct 11, 2026 Mid Description
Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.
